AMGEN announced on May 16, 2024, that it has received FDA approval for its investigational new drug, signaling a significant entry into the targeted oral biologics market where the company is competing against established players like Eli Lilly. This regulatory milestone is expected to drive substantial near-term growth and investment, with analysts optimistic that the drug will become a formidable revenue driver within AMGEN’s future portfolio.